We are a highly-experienced team of drug discovery and development experts focused on making therapies happen that will change the way we age.

matthias steger phd mba
chief executive officer & co-founder
george pavey
chief financial officer (interim)
alicia hegglin phd mba
chief operating officer
karim allam
chief legal & people officer
bob silverman
chief business officer
christian angermayer
co-founder & chairman of the board
aaron weaver cfa
member of the board of directors
stephen helliwell phd
vp discovery biology
patrick schnider phd
vp medicinal chemistry
prof. manuel serrano phd
co-founder & scientific advisor - rejuveron senescence therapeutics
timothy cash phd
co-founder & consultant - rejuveron senescence therapeutics
tristan heintz phd
head of research - rejuveron vascular therapeutics
vasco ledebur de antas de campos phd
head of discovery biology - rejuveron vascular therapeutics
chien chi hsiao
head of medicinal chemistry - rejuveron vascular therapeutics
marianna feretzaki phd
head of discovery biology - rejuveron telomere therapeutics
fedor romanov michailidis phd
head of medicinal chemistry - rejuveron telomere therapeutics
ryan byrne phd
pharmaceutical ai lead
pierre-antoine mudry bba ms
head, corporate finance and investor relations
kara chatelin
accounting officer in finance
joppe nieuwenhuis phd
innovation scout
daniele lionetti msc
finance associate
aksana labokha phd
head of strategic transactions
naffi wade
director compliance & strategic projects
lisa caflisch
lab manager
csaba budai
it operations manager
malaika schroeder ma
director marketing & communications
peter sandbach
advisor communications
dovaine pavinksnyte
team assistant
prof. hideyuki okano md phd
member of the scientific advisory board
prof. lee rubin phd
co-founder - rejuveron vascular therapeutics